Your partner of choice in integrated research

Selvita is a preclinical contract research organization in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development.

Selvita provides its clients with effective drug discovery support based on broad capabilities and deep experience in small molecule drug discovery, starting from target validation up to the selection of a clinical candidate. We powerfully execute fully-integrated drug discovery programs combining all of Selvita’s core skills in biology and chemistry or else provide partially-integrated or stand-alone services utilising selected capabilities optimally matched to the specific needs of our clients.

Our goal is to provide efficacious, safe, and differentiated preclinical candidates.

We place a strong emphasis on translational science, focusing on disease-relevant animal models and ex-vivo studies where appropriate from patient samples, with the discovery process driven by expert medicinal chemistry and ADME/PK. Inflammation, infection, and oncology are our core expertise, accompanied by experience in additional therapeutic areas such as fibrosis, respiratory, and neuroscience.

Selvita provides state-of-the-art analytical services supporting pharmaceutical and biopharmaceutical companies at various stages of drug development and CMC processes by providing contract laboratory services for testing. Our diverse analytical instrumentation and expertise portfolio allow us to meet varied demands, including testing of starting materials, drug substances, intermediates, and final products of small and large molecules. Selvita complies with GMP and GLP requirements to meet the highest industry standards.

Although Selvita has a clear focus on the pharmaceutical industry, our experience in drug discovery and development can be well applied to the broad reach of R&D activities. Analytical and Process Research Groups can successfully support agrochemistry along with flavor & fragrance chemistry by providing GLP-compliant analysis and chemistry services.

We operate globally with more than 900 highly qualified employees at six sites in four countries across Europe and the U.S.

For more information please visit

About Drug Discovery Innovation Programme 2023

Drug Discovery Innovation Programme is an invitation-only and one of the best platforms to learn the latest insights and develop lasting business relationships.

This year’s Drug Discovery Innovation Programme will highlight the challenges discovery pipelines have faced due to COVID-19 and will put a spotlight on thec adoption of technology to finding the solutions.

With over 100+ attendees, learn how modernization in R&D processes is fundamentally changing what the drug discovery research will look like in the next two to five years.

So, join us in 2023 for an in-person experience and 2-days of top-level strategic content and the current scientific insights, networking, and discussions from leading global pharmaceutical R&D executives.

Companies in attendance for 2023 will include Servier Pharmaceuticals, Monte Rosa Therapeutics, University of Oxford, WPD Pharmaceuticals, AISA Therapeutics, Anima Biotech, PDC*line Pharma, Eli Lillly and Company, Symphogen, IRB Barcelona, Axonis Therapeutics, Genentech, Arakis Therapeutics, Johnson & Johnson, Amgen, Revitale Pharma, Progenra Inc, CERo Therapeutics, Merck and much more.

So, why wait? Register with us to learn more!